Chemistry:HDMP-28

From HandWiki
Short description: Stimulant drug
HDMP-28
HDMP-28.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H21NO2
Molar mass283.365 g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

HDMP-28 or methylnaphthidate is a piperidine based stimulant drug, closely related to methylphenidate, but with the benzene ring replaced by naphthalene. It is a potent dopamine reuptake inhibitor, with several times the potency of methylphenidate and a short duration of action,[1] and is a structural isomer of another potent dopamine reuptake inhibitor, N,O-Dimethyl-4-(2-naphthyl)piperidine-3-carboxylate. It has been sold as a designer drug since around 2015.[2]

HDMP-28 and CFT overlay

MMNPC&HDMP-28.png

Most of the TMP analogs of HDMP-28 have SERT Ki values in the range >10,000 and so are selective for dopamine and noradrenaline reuptake, with little or no effect on serotonin. HDMP-28 has high affinity to SERT, and so behaves as a triple reuptake inhibitor.[3]

aEffect of (dl-threo) TMP and analogs on DA and 5-HT Transporters.
Inhibition of specific analogs at displacing CFT from binding to DAT & RTI-55 from binding to SERT
Ar [3H]CFT DAT [3H]DA Uptake [3H]RTI-55 SERT Inhibition by 10 μM D.R. Potency
Ph 83.9 224 ≫10,000 19.6 2.7 1.00
p-F 35.0 142 >10,000 36.9 4.1 3.33
m-Cl 5.1 23.0 >10,000 45.5 4.5 2.42
p-Me 33.0 126 >10,000 45.0 3.8 0.74
p-NH2 34.5 114 ≫10,000 7.9 3.3 2.18
m,p-Cl2 5.3 (2.67)b 7.0 1,064 (>10,000)b 93.3 1.3 7.98
β-Naphthyl 33.9b 11.0c 53.0c 71.6b ND 4.8c
Cocaine 160 404 401 nd 2.5 0.41
aSchweri, et al. (2002);[4] bDavies, et al. (2004);[5] cDeutsch, et al. (2001).[6]

D.R. is the discrimination ratio = [3H]DA ÷ [3H]CFT.

A low D.R. indicates more addictive, whereas a high D.R. indicates low propensity for self-administration.

Legality

HDMP-28 is illegal in Switzerland as of December 2015.[7]

See also

References

  1. "The reinforcing efficacy of psychostimulants in rhesus monkeys: the role of pharmacokinetics and pharmacodynamics". The Journal of Pharmacology and Experimental Therapeutics 307 (1): 356–66. October 2003. doi:10.1124/jpet.103.049825. PMID 12954808. 
  2. Carlier J, Giorgetti R, Varì MR, Pirani F, Ricci G, Busardò FP. Use of cognitive enhancers: methylphenidate and analogs. Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):3-15. doi:10.26355/eurrev_201901_16741 PMID 30657540
  3. "Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites". Bioorganic & Medicinal Chemistry Letters 14 (7): 1799–802. April 2004. doi:10.1016/j.bmcl.2003.12.097. PMID 15026075. 
  4. "Biochemical and behavioral characterization of novel methylphenidate analogs". The Journal of Pharmacology and Experimental Therapeutics 301 (2): 527–35. May 2002. doi:10.1124/jpet.301.2.527. PMID 11961053. 
  5. "Synthesis of methylphenidate analogues and their binding affinities at dopamine and serotonin transport sites". Bioorganic & Medicinal Chemistry Letters 14 (7): 1799–802. April 2004. doi:10.1016/j.bmcl.2003.12.097. PMID 15026075. 
  6. "Synthesis and pharmacology of site specific cocaine abuse treatment agents: a new synthetic methodology for methylphenidate analogs based on the Blaise reaction". European Journal of Medicinal Chemistry 36 (4): 303–11. April 2001. doi:10.1016/s0223-5234(01)01230-2. PMID 11461755. 
  7. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat. https://www.admin.ch/opc/de/classified-compilation/20101220/index.html.